p53 modulates a number of cellular responses to genotoxic stress including cell cycle arrest and apoptosis. Loss of p53 function either by mutation or otherwise may alter the sensitivity of cells to DNA damage. Introduction of a dominant negative p53 mutant (codon 143, Val to Ala) has been shown to confer cisplatin resistance in the chemosensitive human ovarian A2780 carcinoma cell line. Induced resistance of A2780 cells to cisplatin was used as the selection strategy to isolate genetic suppressor elements (GSEs) from retroviral libraries expressing random fragments of human or murine TP53 cDNA (Chapter 4). Six GSEs were identified, encoding either dominant negative mutant peptides or antisense RNA molecules which corresponded to various re...
Although cisplatin is effective in the treatment of different types of tumors, resistance to treatme...
Despite germ cell tumors (GCTs) responding to cisplatin-based chemotherapy at a high rate, a subset ...
The development of resistance to anticancer drugs poses one of the major obstacles to improving the ...
p53 modulates a number of cellular responses to genotoxic stress including cell cycle arrest and apo...
Cisplatin is a chemotherapeutic agent which is thought to exert its cytotoxic effects by causing DNA...
Cis-dichlorodiammineplatinum(II) (cisplatin) is widely used as an anti-cancer agent to treat various...
Most gene therapy strategies related to p53 concentrate on the restoration of the activity of mutant...
Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in resistance of o...
Background: Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in res...
The p53 tumor suppressor protein is a critical mediator of cell cycle arrest and apoptosis in respon...
The efficacy of cisplatin-based chemotherapy in cancer is limited by the occurrence of innate and ac...
grantor: University of TorontoCisplatin is a chemotherapeutic agent commonly used, though ...
Abstract CIRCUMVENTING CISPLATIN RESISTANCE IN OVARIAN CANCERS THROUGH REACTIVATION OF P53 BY NON-CR...
A panel of tumour models used extensively for in vivo evaluation of new drugs was characterised for ...
p53 is a transcription factor activated by genotoxic stress. Dependent on the level of DNA damage, p...
Although cisplatin is effective in the treatment of different types of tumors, resistance to treatme...
Despite germ cell tumors (GCTs) responding to cisplatin-based chemotherapy at a high rate, a subset ...
The development of resistance to anticancer drugs poses one of the major obstacles to improving the ...
p53 modulates a number of cellular responses to genotoxic stress including cell cycle arrest and apo...
Cisplatin is a chemotherapeutic agent which is thought to exert its cytotoxic effects by causing DNA...
Cis-dichlorodiammineplatinum(II) (cisplatin) is widely used as an anti-cancer agent to treat various...
Most gene therapy strategies related to p53 concentrate on the restoration of the activity of mutant...
Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in resistance of o...
Background: Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in res...
The p53 tumor suppressor protein is a critical mediator of cell cycle arrest and apoptosis in respon...
The efficacy of cisplatin-based chemotherapy in cancer is limited by the occurrence of innate and ac...
grantor: University of TorontoCisplatin is a chemotherapeutic agent commonly used, though ...
Abstract CIRCUMVENTING CISPLATIN RESISTANCE IN OVARIAN CANCERS THROUGH REACTIVATION OF P53 BY NON-CR...
A panel of tumour models used extensively for in vivo evaluation of new drugs was characterised for ...
p53 is a transcription factor activated by genotoxic stress. Dependent on the level of DNA damage, p...
Although cisplatin is effective in the treatment of different types of tumors, resistance to treatme...
Despite germ cell tumors (GCTs) responding to cisplatin-based chemotherapy at a high rate, a subset ...
The development of resistance to anticancer drugs poses one of the major obstacles to improving the ...